Type 2 immunity in asthma

Table 1 Biologicals targeting Th2 inflammation and their main effects

Drug	Exacerbations	Lung Function	QoL
Mepolizumab (ANTI IL-5)	Reduction [92, 94,95,96]	Increase [92, 96]; no variation in FEV1 [94, 96]	Increase [94, 97, 98], no variation in QoL [96]
Reslizumab (ANTI IL-5)	Reduction [100, 101]	Increase of FEV1 [102]	Increase of QoL [100]
Benralizumab (ANTI IL-5Ra)	Reduction [103, 106,107,108,109]	Increase of FEV1 [107,108,109]; no variation [106]	Increase of QoL [107,108,109]; no variation [106]
Pitrakinra (ANTI IL-4)	Reduction in homozygous for the rs8832 common G allele, rs1029489, and the intronic SNPs rs3024585, rs3024622 and rs4787956 [111]	Reduction [111]	n.a.
Dupilumab (ANTI IL-4rα)	Reduction [112, 113]	Increase of FEV1 [112, 113]	Increase of QoL [14, 112]
Lebrikizumab (ANTI IL-13)	Reduction in high periostin group [115]	Increase of FEV1 in high periostin group [115, 116], response in high periostin, IgE and eosinophils group, [117], no variation [118]	No variation [115]
Tralokinumab (ANTI IL-13)	Reduction in high-periostin and high-DPP-4 groups [119]	Increase in high-periostin and high-DPP-4 groups [119]	Increase of QoL [120]
Tezepelumab (ANTI TSLP)	Reduction [122]	Increase [122]	Increase at medium and high dosage [122]

ISSN: 1939-4551